Boxin Bio is a company dedicated to leading industries such as large health industry, medical investment, brand operation and service.

In 2003, Mr. Jiang Miao, the founder of the company, worked closely with the Chinese Academy of Military Medical Sciences in the field of biomedicine and health, and continued to focus on research in blood transfusion safety and plasma virus inactivation. In 2009, he successfully developed independent intellectual property rights. The first generation of plasma virus inactivation instrument, approved by the State Food and Drug Administration, was formally produced and put into clinical use.

In 2013, the company undertook the national “Twelfth Five-Year” scientific and technological major special project “AIDS and viral hepatitis prevention and treatment” and the military ’s “Tenth Five-Year” directive project. Through close cooperation, the application innovation of the second-generation plasma virus inactivation instrument, namely the AIDS treatment instrument, was successfully achieved, and passed the scientific and technological achievements appraisal by the Ministry of Science and Technology.

In the same period, the company strengthened cooperation with scientific research institutions such as China Center for Disease Control and Prevention, Beijing Ditan Hospital of Capital Medical University, State Key Laboratory of Diagnosis and Treatment of Infectious Diseases of Zhejiang University, and internationally renowned biotechnology company Thermo Fisher, focusing on AIDS treatment and HIV virus detection , Continuous technological innovation, continuous investment in scientific research, jointly developed rapid AIDS drug resistance testing technology and new treatment methods.

At present, the company's product pipeline covers AIDS treatment, HIV viral load + drug resistance + subtype comprehensive detection technology and prostate drugs. The company is committed to using high-tech innovative technical means, focusing on continuous efforts in the field of AIDS diagnosis and treatment, to overcome difficulties, and provide a full range of services for the majority of AIDS patients to maintain a healthy life.


August 2003
JY-1 plasma virus inactivation instrument was successfully developed
December 2009
The medical device registration certificate No.: GSYJX(Z)Z 2009 No. 3451019 was obtained
December 2016
The cooperation agreement was signed with the Infection Center of Beijing YouAn Hospital on "immune reconstitution therapy for HIV drug-resistant patients"
February 2017
In February, the first large-scale clinical trial was conducted in Beijing YouAn Hospital, Capital Medical University
May 2017
In May, the second clinical trial was conducted in the Second People's Hospital of Tianjin
April 2018
In April, the patent for invention of plasma viral inactivation instrument was applied (Patent No.: 201810368896.7)
April 2018
In April, invention patent on photochemical preparation method of autologous plasma inactivated vaccine for treatment of AIDS was obtained(Patent No: 201810368096.5)
May 2018
In May, the project "Study on the efficacy and safety of non-drug fusion blocking therapy in the treatment of HIV/AIDS" passed the acceptance by the famous national expert group on AIDS prevention and control
September 2019
In September, the clinical trials were conducted simultaneously in Chongqing, Tianjin and Beijing
September 2019
In September, the in vitro HIV standard/resistant strain inactivation validation test of BX-I AIDS therapeutic apparatus was completed in State Key Laboratory of Infectious Disease Diagnosis and Treatment (P3 Laboratory), Zhejiang University